Is Ozempic Linked to Gastroparesis? Understanding the Evidence

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Wellness to Specific Pharmaceutical Risk

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be wondering whether the medication could be causing delayed gastric emptying. Medical literature has long recognized that certain drugs can affect gastrointestinal motility, and recent reports have focused on semaglutide's potential role in gastroparesis. This guide reviews the documented cases and clinical context surrounding Ozempic and gastroparesis.

Bridging to Ozempic and Gastroparesis

Building on the legacy of general health communication, we now focus on a specific pharmaceutical agent: Ozempic (semaglutide). This glucagon-like peptide-1 (GLP-1) receptor agonist is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Its mechanism involves slowing gastric emptying, which contributes to its glucose-lowering effects but also raises concerns about gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. Clinical presentation of gastroparesis overlaps significantly with the gastrointestinal adverse reactions reported in Ozempic trials. In placebo-controlled studies, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 15.3% for placebo, 32.7% for Ozempic 0.5 mg, and 36.4% for Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms mirror those of gastroparesis, though the label does not explicitly list gastroparesis as a reported adverse reaction.

Mechanistic Evidence and Clinical Implications

Mechanistically, GLP-1 receptor agonists like Ozempic delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can mimic or exacerbate gastroparesis. This effect is dose-dependent and more pronounced during initial treatment or dose escalation. The pharmacologic action is intended to improve postprandial glucose control but can lead to persistent symptoms in susceptible individuals. The label notes that Ozempic has not been studied in patients with a history of pancreatitis, and it recommends considering other antidiabetic therapies in such patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, no specific warning about gastroparesis is included, despite the overlap in symptoms and mechanism. Risk considerations for affected patients center on the adequacy of warnings. The label does not explicitly mention gastroparesis as a potential adverse reaction, which may leave patients and clinicians unaware of the risk. Causation-related considerations require evaluating the temporal relationship between Ozempic exposure and symptom onset. The majority of gastrointestinal adverse reactions occur during dose escalation, suggesting a timeline of days to weeks after initiation or dose increase. For patients who develop persistent nausea, vomiting, or early satiety, the possibility of drug-induced gastroparesis should be considered. Discontinuation of Ozempic may lead to symptom resolution, but in some cases, symptoms may persist, requiring further evaluation and management. The timeline between exposure and documented harm is supported by trial data showing that gastrointestinal adverse reactions are most common during dose escalation. In the placebo-controlled trials, the majority of reports of nausea, vomiting, and/or diarrhea occurred during this period (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This suggests that harm can manifest relatively quickly after starting treatment or increasing the dose. For patients who develop severe or persistent symptoms, the risk of gastroparesis should be evaluated, and alternative therapies considered. In summary, while Ozempic is effective for glycemic control and cardiovascular risk reduction, its gastrointestinal adverse effects—including those consistent with gastroparesis—are common and dose-dependent. The current labeling does not explicitly warn about gastroparesis, which may represent a gap in risk communication. Patients experiencing persistent gastrointestinal symptoms during Ozempic therapy should be evaluated for gastroparesis, and clinicians should weigh the benefits and risks, particularly in those with pre-existing gastrointestinal conditions.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. This can mimic or exacerbate gastroparesis, a condition of delayed gastric emptying. Clinical trials show high rates of gastrointestinal adverse reactions such as nausea, vomiting, and early satiety, which overlap with gastroparesis symptoms. However, the drug label does not explicitly list gastroparesis as an adverse reaction (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

How common are gastrointestinal side effects with Ozempic?

In placebo-controlled trials, gastrointestinal adverse reactions occurred in 32.7% of patients on Ozempic 0.5 mg and 36.4% on 1 mg, compared to 15.3% on placebo. Discontinuation due to GI issues was 3.1% for 0.5 mg and 3.8% for 1 mg, versus 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Should I stop taking Ozempic if I have gastroparesis symptoms?

If you experience persistent nausea, vomiting, or early satiety while on Ozempic, consult your healthcare provider. They may evaluate for gastroparesis and consider alternative therapies. Do not discontinue medication without medical advice.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.